CareDx Announces Victory for Transplant Community Confirming Long-Term Medicare Coverage for AlloSure and AlloMap Testing

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to withdraw a draft LCD that would limit coverage for noninvasive blood-based surveillance testing for allograft rejection. Combined with the removal of restrictive language in the accompanying Billing Article in February 2024 and based on discussions with CMS, CareDx believes long-term coverage for AlloSure, AlloMap, and HeartCare has been effectively restored.

““We appreciate the Agency and its local contractors for listening to the voices of thousands of patients and clinicians who have tirelessly advocated for access to noninvasive surveillance testing based on its clinical utility in detecting early signs of rejection. We believe their efforts were instrumental in restoring long-term Medicare coverage,” said John W. Hanna, President and CEO of CareDx.